When should therapeutic phlebotomy be initiated in hereditary hemochromatosis?

When to Initiate Therapeutic Phlebotomy for Hemochromatosis

Therapeutic phlebotomy should be initiated immediately in patients with confirmed hereditary hemochromatosis who have elevated serum ferritin (>300 µg/L in men or >200 µg/L in women) and transferrin saturation >45%, regardless of symptoms. 1, 2, 3

Diagnostic Thresholds That Trigger Treatment

Begin weekly phlebotomy when:

• Serum ferritin exceeds 300 µg/L in men or 200 µg/L in women 1, 4, 5
• Transferrin saturation is >45-55% 6
• Genetic confirmation shows C282Y homozygosity or compound heterozygosity 6

Do not wait for symptoms to develop – the goal is to prevent irreversible organ damage, not to treat established disease. 6, 7

Clinical Scenarios Requiring Immediate Phlebotomy

Asymptomatic Patients with Iron Overload

• Start phlebotomy in asymptomatic C282Y homozygotes with ferritin <1000 µg/L and normal liver enzymes without requiring liver biopsy first 1, 3
• This represents safe, inexpensive preventive therapy that prevents progression to cirrhosis and diabetes 6, 2

Patients with Any End-Organ Damage

• Initiate phlebotomy at any ferritin level when end-organ damage is present (liver disease, cardiomyopathy, diabetes, arthropathy, skin hyperpigmentation) 1
• Treatment before cirrhosis develops results in 10-year survival equivalent to age-matched controls 6

Patients with Established Cirrhosis

• Begin phlebotomy even with advanced liver disease, as it may produce histologic improvement in 13-50% of cases, with greatest benefit in early fibrosis 6
• However, established cirrhosis is generally irreversible 2

Treatment Protocol Once Initiated

Induction Phase

• Remove 500 mL blood weekly (approximately 200-250 mg iron per session) 1, 2, 3
• Continue until serum ferritin reaches 50-100 µg/L 1, 2, 3
• Check hemoglobin before every session 1, 2, 3
• Stop phlebotomy if hemoglobin falls below 11 g/dL; reduce frequency if below 12 g/dL 1, 3
• Monitor ferritin every 10-12 phlebotomies (≈3 months); increase to every 1-2 sessions once ferritin drops below 200 µg/L 1, 2, 3

Maintenance Phase

• Continue phlebotomy every 2-6 months lifelong to maintain ferritin 50-100 µg/L 1, 2, 3
• Monitor ferritin every 6 months during maintenance 1, 2, 3

Critical Safety Considerations

Cardiac Disease Patients

Patients with cardiomyopathy or arrhythmias require slower phlebotomy schedules because rapid iron mobilization creates a toxic low-molecular-weight iron pool that can precipitate sudden cardiac death. 1, 2, 3, 4 Consider erythrocytapheresis or iron chelation as safer alternatives in this population. 1, 2

Anemic Patients

• Phlebotomy is contraindicated when hemoglobin is <11 g/dL 1, 3
• Use iron chelation therapy (deferoxamine 20-40 mg/kg/day subcutaneously) instead when phlebotomy cannot be tolerated 1, 2

Common Pitfalls to Avoid

The most serious error is continuing phlebotomy when ferritin falls below 50 µg/L – this triggers compensatory iron absorption and produces symptomatic iron deficiency that can persist for months. 3 Intensify monitoring to every 1-2 sessions once ferritin drops below 200 µg/L to prevent overshooting the target. 1, 2, 3

Do not delay treatment waiting for genetic confirmation if phenotypic testing (elevated ferritin and transferrin saturation) strongly suggests hemochromatosis and the patient has evidence of iron overload. 6

Avoid vitamin C supplements entirely during treatment – vitamin C accelerates iron mobilization to potentially hazardous levels and increases oxidative stress. 1, 2, 3

Evidence Quality Note

While no randomized controlled trials exist comparing early versus delayed phlebotomy (such trials would be unethical given current understanding), multiple case series demonstrate that treatment initiated before cirrhosis develops normalizes survival compared to untreated controls. 6 The evidence supporting phlebotomy is accepted as standard of care by hepatology experts despite the absence of Level 1 evidence. 6